RT Journal Article
SR Electronic
T1 COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.20.21262328
DO 10.1101/2021.08.20.21262328
A1 Daniel Junker
A1 Alex Dulovic
A1 Matthias Becker
A1 Teresa R. Wagner
A1 Philipp D. Kaiser
A1 Bjoern Traenkle
A1 Katharina Kienzle
A1 Stefanie Bunk
A1 Carlotta Struemper
A1 Helene Haeberle
A1 Kristina Schmauder
A1 Natalia Ruetalo
A1 Nisar Malek
A1 Karina Althaus
A1 Michael Koeppen
A1 Ulrich Rothbauer
A1 Juliane S. Walz
A1 Michael Schindler
A1 Michael Bitzer
A1 Siri Göpel
A1 Nicole Schneiderhan-Marra
YR 2021
UL http://medrxiv.org/content/early/2021/12/06/2021.08.20.21262328.abstract
AB As global vaccination campaigns against SARS-CoV-2 proceed, there is particular interest in the longevity of immune protection, especially with regard to increasingly infectious virus variants. Neutralizing antibodies (Nabs) targeting the receptor binding domain (RBD) of SARS-CoV-2 are promising correlates of protective immunity and have been successfully used for prevention and therapy. As SARS-CoV-2 variants of concern (VOCs) are known to affect binding to the ACE2 receptor and by extension neutralizing activity, we developed a bead-based multiplex ACE2-RBD inhibition assay (RBDCoV-ACE2) as a highly scalable, time-, cost-, and material-saving alternative to infectious live-virus neutralization tests. By mimicking the interaction between ACE2 and the RBD, this serological multiplex assay allows the simultaneous analysis of ACE2 binding inhibition to the RBDs of all SARS-CoV-2 VOCs and variants of interest (VOIs) in a single well. Following validation against a classical virus neutralization test and comparison of performance against a commercially available assay, we analyzed 266 serum samples from 168 COVID-19 patients of varying severity. ACE2 binding inhibition was reduced for ten out of eleven variants examined compared to wild-type, especially for those displaying the E484K mutation such as VOCs beta and gamma. ACE2 binding inhibition, while highly individualistic, positively correlated with IgG levels. ACE2 binding inhibition also correlated with disease severity up to WHO grade 7, after which it reduced.Competing Interest StatementNSM was a speaker at Luminex user meetings in the past. The Natural and Medical Sciences Institute at the University of Tuebingen is involved in applied research projects as a fee for services with the Luminex Corporation. The other authors declare no competing interests.Funding StatementThis work was financially supported by the State Ministry of Baden-Wuerttemberg for Economic Affairs, Labour and Housing Construction (grant number FKZ 3-4332.62-NMI-68).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Collection of samples and the execution of this study was approved by the Ethics committee of the Eberhard Karls University Tuebingen and the University Hospital Tuebingen under the ethical approval numbers 188/2020A and 764/2020/BO2 to Prof. Dr. Michael Bitzer. All participants signed the broad consent of the Medical Faculty Tuebingen for sample collection. Samples that were used for assay validation had their collection approved by the Ethics committee of the Eberhard Karls University Tuebingen and the University Hospital Tuebingen under the ethical approval numbers 222/2020/BO2 to Dr. Karina Althaus and 179/2020/BO2 to Prof. Dr. Juliane Walz. For all assay validation samples, written informed consent was obtained.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated in this manuscript is available from the authors upon request.